Results 101 to 110 of about 278,336 (309)

Clinical impact of molecular characterization on liquid biopsy in patients with advanced NSCLC

, 2022
reservedPresupposti dello studio: il trattamento delle neoplasie polmonari in stadio avanzato è stato rivoluzionato dall’avvento delle terapie a bersaglio molecolare e dell’immunoterapia.
ALAM, M ASHRAFUL
core  

A Panel of Circulating Exosomal sncRNAs Associated With Lung Cancer Risk up to 10 Years in Advance

Advanced Science, EarlyView.
Lung cancer is often diagnosed too late, and current screening overlooks many people at risk. In a long‐term study of smokers, a panel of small non‐coding RNAs carried in blood exosomes signals elevated lung cancer risk up to ten years before diagnosis, pointing toward a blood‐based tool for earlier risk detection.
Zhuokun Feng, Masaki Nasu, Ayman Abdul‐Ghani, Yu Chen, Shaoqiu Chen, Isam Mohd Ibrahim, Hanqiu Zhang, Lauren Higa, Zitong Gao, Hua Yang, Raphael Bueno, Loïc Le Marchand, Youping Deng   +12 more
wiley   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer type, with 80-85% prevalence. Usually, NSCLC is treated by chemotherapy and radiotherapy in collaboration with gefitinib or other anticancer drugs.
Precella Silvia, Jeremi Ongko, Yulanda Antonius   +2 more
doaj   +1 more source

Tests for detection of ROS1 gene alterations in people with non-small cell lung cancer (NSCLC): A Health Technology Assessment. [PDF]

, 2021
Key messages: The Norwegian Institute of Public Health has been commissioned to evaluate molecular tests for the identification of somatic ROS1 gene alterations in people with locally advanced or metastatic non-small cell lung cancer (NSCLC). People with
Hamidi Ashtiani, Vida, Flodgren, Gerd Monika   +1 more
core  

Agent‐Based Simulations of Lung Tumor Evolution Suggest That Ongoing Cell Competition Drives Realistic Clonal Expansions

Advanced Science, EarlyView.
Computational simulations of tumor evolution are increasingly used to infer the rules underlying cancer growth, with the goal of one day recommending tailored treatments. Here we show that the properties of lung cancer sequencing data are best replicated by a model which assumes that cells compete both to proliferate and survive. ABSTRACT Computational
Helena Coggan, James R. M. Black, Carlos Martínez‐Ruiz, Kristiana Grigoriadis, Jasmin Fisher, Nicholas McGranahan   +5 more
wiley   +1 more source

The effect of health care expenditures on survival in locally advanced and metastatic Non Small Cell Lung Cancer [PDF]

Context: The significant survival benefit of chemotherapy over best supportive care for locally advanced and metastatic NSCLC has been amply demonstrated in the literature.
Paul Rebattu, Lionel Perrier, Frédéric Gomez, Marie-Odile Carrère, Magali Morelle, Nathalie Havet, Bertrand Favier, Anthony Montella, David Pérol   +8 more
core  

Novel Biological Therapy in Non-small Cell Lung Cancer

, 2023
This thesis discusses the epidemiology, risk factors, diagnosis, staging, aetiology, classification and treatment of Non small-cell lung cancer (NSCLC), specifically delving into the novel biological therapies being used and researched today. This thesis
Alawad, Mohamed
core  

Crosstalk Between CTSB+ Glioblastoma Cells and S100A10+ Macrophages: A Self‐Reinforcing Circuit Promotes Immune Evasion and Limits Response to Immunotherapy

Advanced Science, EarlyView.
In glioblastoma, M2‐polarized macrophages secrete IL‐6, which activates STAT3 signaling in tumor cells to upregulate CTSB. Tumor‐derived CTSB binds the C‐terminus of macrophage S100A10, reinforcing M2 polarization and further IL‐6 secretion, thereby establishing a feedforward IL‐6/STAT3/CTSB/S100A10 loop. This cascade drives tumor growth, invasion, and
Hao Zhang, Nan Zhang, Xisong Liang, Jie Wen, Ziyu Dai, Wantao Wu, Shuyu Li, Songshan Feng, Zaoqu Liu, Zhiwei Xia, Peng Luo, Quan Cheng   +11 more
wiley   +1 more source

MET overexpression and gene amplification in NSCLC: a clinical perspective

, 2013
Lorenza Landi, Gabriele Minuti, Armida D'Incecco, Jessica Salvini, Federico CappuzzoMedical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, ItalyAbstract: The transmembrane tyrosine kinase mesenchymal-epidermal transition (MET)
D'Incecco A, Cappuzzo F, Landi L, Minuti G, Salvini J   +4 more
core